$Apple (AAPL.US)$ iOS 18 was a failure…its as if Apple saw Microsoft’s rollout of Windows 11 and said “we can do far worse”….

US stock market tumbled last Friday as the post-election rally faltered, likely due to the latest inflation data and Jerome Powell’s slightly hawkish stance.
The market has already given up half of the post-election gains. So! Is the post-election rally over?
$Bitcoin (BTC.CC)$   $S&P 500 Index (.SPX.US)$ $E-mini NASDAQ 100 Futures(DEC4) (NQmain.US)$ $Vanguard S&P 500 ETF (VOO.US)$ $SPDR Dow Jones Industrial Average Trust (DIA.US)$ $KraneShares CSI China Internet ETF (KWEB.US)$ $Salesforce (CRM.US)$ $Super Micro Computer (SMCI.US)$ $Advanced Micro Devices (AMD.US)$ $Taiwan Semiconductor (TSM.US)$ $Broadcom (AVGO.US)$ $Johnson & Johnson (JNJ.US)$ $Arm Holdings (ARM.US)$

$Unicycive Therapeutics (UNCY.US)$
Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024
Unicycive Therapeutics (UNCY) presented multiple studies at ASN Kidney Week 2024, highlighting progress on oxylanthanum carbonate (OLC) and UNI-494. The late-breaking presentation showed OLC enabled serum phosphate control in >90% of chronic kidney disease pati...

$Unicycive Therapeutics (UNCY.US)$
Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
Unicycive Therapeutics announced FDA acceptance of its New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for treating hyperphosphatemia in chronic kidney disease patients on dialysis. The FDA set a PDUFA target date of June 28, 2025. OLC aim...

$Ardelyx (ARDX.US)$
The price drop was caused by a perfect storm of negative factors. In pre-market trading hours, one or more whales received word of the court decision ahead of most other investors: probably through Barchart and premium terminal services (or boots-on-the-ground observers). If you look at the volume chart, most of the trade volume occurred very early, and the daily trading volume is well over 4x the daily average.
Because there was this big ...

$Ardelyx (ARDX.US)$ what is going on

$Valneva (VALN.US)$
I notice that when people talk about Valneva, you hear endless talk about Lyme & Chikungunya, but there is almost no talk about SV4, a tetravalent bioconjugate vaccine candidate against shigellosis that is entering Phase 2. It seems that most of the talk regarding this centers around children in third world underdeveloped countries, but there is a possible huge market if it gets worked into the standard childhood vaccine sched...